Viatris sues Novo Nordisk over Wegovy generic patent claims
by@Reuters
Summary
Mylan Pharmaceuticals has initiated a legal battle against Danish pharmaceutical giant Novo Nordisk in Delaware federal court, seeking a declaration that its proposed generic version of the weight management drug Wegovy does not infringe on Novo's patent rights related to the administration method of the drug. This lawsuit comes despite Novo earning nearly $31 billion last year from Wegovy and its counterpart Ozempic, both of which are GLP-1 medications administered via single-dose pens. Under current patent protections, generic versions of Wegovy and Ozempic cannot enter the US market until 2032, when patents on the active ingredient semaglutide expire.
Tokens
$VTRS$NVO
Analysis
Viatris: Viatris is a global pharmaceutical company that develops, manufactures, and markets generic and branded medicines across multiple therapeutic areas. Through its Mylan Pharmaceuticals subsidiary, the company has filed a lawsuit in Delaware federal court seeking a ruling that its proposed generic version of Wegovy does not infringe Novo Nordisk's patents on the drug's administration method. Novo Nordisk: Novo Nordisk is a Danish pharmaceutical company focused on treatments for diabetes, obesity, and related conditions, including the GLP-1 receptor agonist medications Wegovy and Ozempic. The company is the defendant in the current patent lawsuit brought by Viatris, where it is defending its intellectual property rights covering the single-dose pen administration of Wegovy. Shannon Bloodworth: Shannon Bloodworth is an attorney affiliated with Ashurst Perkins Coie. She is representing Mylan Pharmaceuticals in the patent litigation against Novo Nordisk filed in the US District Court for the District of Delaware. Mylan Pharmaceuticals: Mylan Pharmaceuticals is a subsidiary of Viatris specializing in the development and production of generic pharmaceuticals. It is the named plaintiff in the Delaware federal court case seeking a declaratory judgment of non-infringement regarding Novo Nordisk's patent on Wegovy administration methods. Legal Action: Pharmaceutical patent disputes often involve declaratory judgment actions filed by generic makers to resolve infringement questions before product launch. Drug Category: Wegovy belongs to the GLP-1 class of medications used for weight management and is administered via single-dose pens.
Categories
macropolitics